<DOC>
	<DOCNO>NCT01844895</DOCNO>
	<brief_summary>The purpose study implement substudy approximately 120 rheumatoid arthritis ( RA ) subject compare steady-state serum trough concentration ( Cminss ) , Cmax area curve ( AUC ) dose interval ( TAU ) subcutaneous ( SC ) Abatacept injection 125 mg via autoinjector via BD Hypakâ„¢ Physiolis prefilled syringe .</brief_summary>
	<brief_title>Methotrexate-Inadequate Response Autoinjector Device Sub Study</brief_title>
	<detailed_description>Study Classification : - Safety : show drug safe condition propose use - Efficacy : measure intervention 's influence disease health condition - Safety/Efficacy - Pharmacokinetics : action drug body period time include process absorption , distribution localization tissue , biotransformation , excretion compound .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Subjects treat long term ( LT ) openlabel SC Abatacept least 3 month Must continue meet inclusion criterion specify main IM101174 Study Protocol Participation previous device substudy ( implement Amendment 10 ) Must continue meet exclusion criterion specify main IM101174 Study Protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>